.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
AstraZeneca
Daiichi Sankyo
Federal Trade Commission
Healthtrust
Covington
Moodys
Argus Health
McKinsey
Johnson and Johnson

Generated: September 19, 2017

DrugPatentWatch Database Preview

Perrigo Company Profile

« Back to Dashboard

What is the competitive landscape for PERRIGO, and what generic alternatives to PERRIGO drugs are available?

PERRIGO has two hundred and twelve approved drugs.

There are seven US patents protecting PERRIGO drugs on PERRIGO drugs in the past three years. There is one tentative approval on PERRIGO drugs.

There are ninety patent family members on PERRIGO drugs in twenty-four countries.

Summary for Applicant: Perrigo

Patents:7
Tradenames:108
Ingredients:92
NDAs:212
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo R And D
IBUPROFEN SODIUM
ibuprofen sodium
TABLET;ORAL206581-001Aug 3, 2015OTCNoNo► Subscribe► Subscribe► Subscribe
Perrigo Pharma Intl
BUTOCONAZOLE NITRATE
butoconazole nitrate
CREAM;VAGINAL019881-001Feb 7, 1997DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Perrigo
IBUPROFEN
ibuprofen
TABLET;ORAL075995-001Mar 14, 2002OTCNoNo► Subscribe► Subscribe► Subscribe
Perrigo R And D
CETIRIZINE HYDROCHLORIDE ALLERGY
cetirizine hydrochloride
TABLET;ORAL078336-001Dec 27, 2007OTCNoNo► Subscribe► Subscribe► Subscribe
Perrigo R And D
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF
cetirizine hydrochloride
SYRUP;ORAL090254-001Apr 9, 2008OTCNoNo► Subscribe► Subscribe► Subscribe
Perrigo New York
DESONIDE
desonide
OINTMENT;TOPICAL017426-001Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Perrigo
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE
loperamide hydrochloride; simethicone
TABLET, CHEWABLE;ORAL076029-001Aug 30, 2002OTCNoYes► Subscribe► Subscribe► Subscribe
Perrigo New York
AMMONIUM LACTATE
ammonium lactate
LOTION;TOPICAL075570-001Jun 23, 2004ABRXNoYes► Subscribe► Subscribe► Subscribe
Perrigo
TAB-PROFEN
ibuprofen
TABLET;ORAL072095-001Dec 8, 1987OTCNoNo► Subscribe► Subscribe► Subscribe
Perrigo
IBUPROFEN
ibuprofen
TABLET, CHEWABLE;ORAL076359-002Jan 16, 2004OTCNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Perrigo

Paragraph IV activity for PERRIGO drugs

Drugname Dosage Strength Tradename Submissiondate
clindamycin phosphate
Vaginal Cream2%
CLINDESSE
2/5/2015
butoconazole nitrate
Vaginal Cream2%
GYNAZOLE-1
12/23/2009
budesonide
Enteric Coated Capsules3 mg
ENTOCORT EC
2/1/2008

Non-Orange Book Patents for Perrigo

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,071,075Dermal penetration enhancers and drug delivery systems involving the same► Subscribe
6,416,778 Pharmaceutical preparations and methods for their regional administration► Subscribe
6,929,801 Transdermal delivery of antiparkinson agents► Subscribe
6,916,487 Transdermal delivery of antiemetics► Subscribe
6,916,486 Transdermal delivery of analgesics► Subscribe
7,438,203Dermal penetration enhancers and drug delivery systems involving same► Subscribe
7,094,422Topical delivery of antifungal agents► Subscribe
7,387,789Transdermal delivery of non-steroidal anti-inflammatory drugs► Subscribe
6,652,874 Pharmaceutical preparations and methods for their regional administration► Subscribe
6,998,138Topical delivery of anti-alopecia agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Perrigo Drugs

Country Document Number Estimated Expiration
Germany122012000019► Subscribe
South Korea100831386► Subscribe
European Patent Office1611878► Subscribe
Portugal102854► Subscribe
Germany122012000021► Subscribe
Canada2259764► Subscribe
Japan4462818► Subscribe
Australia5922798► Subscribe
Portugal977555► Subscribe
Japan2007326867► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Perrigo Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
972Luxembourg► Subscribe91972, EXPIRES: 20220219
/2015Austria► SubscribePRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
C0032Belgium► SubscribePRODUCT NAME: PANTOPRAZOL. NATR. SESQUIHYDRAS PANTOPRAZOLE; NAT. REGISTRATION NO/DATE: 127 IS 98 F 3 19960222; FIRST REGISTRATION: SE 12131 19940506
01C/013Belgium► SubscribePRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
00221Netherlands► SubscribePRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
13/055Ireland► SubscribePRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
00C/027Belgium► SubscribePRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
C/GB08/005United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
C0001France► SubscribePRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
C/GB04/032United Kingdom► SubscribePRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Medtronic
Federal Trade Commission
Chubb
Accenture
Colorcon
Novartis
Healthtrust
Daiichi Sankyo
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot